Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | CHIEF TECHNICAL OPS OFFICER | July 09, 2026 | July 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PTC THERAPEUTICS, INC.
Report date July 09, 2026 · Filed July 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,299 |
Ending reported balance
After 2026-07-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-09 · Exercise / conversion · Acquired 2,464 · Balance 62,763 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. Row 2 · 2026-07-09 · Sale · Disposed 2,464 · Balance 60,299 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $90.00 to $90.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.54 · Expires 2035-01-02 | Direct | 45,036 |
Reported balance
After 2026-07-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-09 · Exercise / conversion · Disposed 2,464 · Balance 45,036 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F3: This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 2,899 |
Reported balance
Holding disclosure · report date 2026-07-09 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,899 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025.
F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $90.00 to $90.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3: This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2026 Filed Feb 20, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 65 | $69.36 | $4,508.40 |
DisclosureSEC source: 0001578850-26-000008 · form4-02202026_050201.xml · nonDerivative · entry 2 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 6,726 F2 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 217 RSUs from a February 15, 2024 grant of 870 RSUs. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,056 | $69.36 | $211,964.16 |
DisclosureSEC source: 0001578850-26-000008 · form4-02202026_050201.xml · nonDerivative · entry 1 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,140 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,750 RSUs from a February 15, 2024 grant of 19,000 RSUs and the vesting of 3,000 RSUs from a February 15, 2024 grant of 6,000 RSUs. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 59 | $76.45 | $4,510.55 |
DisclosureSEC source: 0001578850-26-000006 · form4-01122026_050101.xml · nonDerivative · entry 2 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 6,791 F2 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 195 RSUs from a January 7, 2022 grant of 780 RSUs. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 881 | $76.45 | $67,352.45 |
DisclosureSEC source: 0001578850-26-000006 · form4-01122026_050101.xml · nonDerivative · entry 1 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,196 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 3,600 RSUs from a January 7, 2022 grant of 14,400 RSUs. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 52 | $77.48 | $4,028.96 |
DisclosureSEC source: 0001578850-26-000004 · form4-01082026_050101.xml · nonDerivative · entry 4 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 6,850 F4 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 177 RSUs from a January 5, 2023 grant of 710 RSUs. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,026 | $77.48 | $79,494.48 |
DisclosureSEC source: 0001578850-26-000004 · form4-01082026_050101.xml · nonDerivative · entry 3 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,077 F3 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,250 RSUs from a January 5, 2023 grant of 17,000 RSUs. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 54 | $76.95 | $4,155.30 |
DisclosureSEC source: 0001578850-26-000004 · form4-01082026_050101.xml · nonDerivative · entry 2 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 6,902 F2 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 178 RSUs from a January 3, 2025 grant of 715 RSUs. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,279 | $76.95 | $98,419.05 |
DisclosureSEC source: 0001578850-26-000004 · form4-01082026_050101.xml · nonDerivative · entry 1 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,103 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,750 RSUs from a January 3, 2025 grant of 19,000 RSUs. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 43,750 | $0.00 Strike: $76.74 | $0.00 |
DisclosureSEC source: 0001578850-26-000002 · form4-01062026_050126.xml · derivative · entry 3 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,750 Underlying: Common Stock · 43,750 shares Expires 2036-01-01 F3 · derivative.exercise_date: This option was granted on January 2, 2026, and vests over four years, with 25% of the shares underlying the option vesting on January 2, 2027, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 2, 2027. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 520 | $0.00 | $0.00 |
DisclosureSEC source: 0001578850-26-000002 · form4-01062026_050126.xml · nonDerivative · entry 2 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 6,956 F1 · shares: Restricted stock units granted on January 2, 2026 that vest in four equal installments over four years, commencing on January 2, 2027. F2 · balance_after: Includes 257 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended December 31, 2025. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001578850-26-000002 · form4-01062026_050126.xml · nonDerivative · entry 1 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,382 F1 · shares: Restricted stock units granted on January 2, 2026 that vest in four equal installments over four years, commencing on January 2, 2027. F2 · balance_after: Includes 257 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended December 31, 2025. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,399 | $0.00 Strike: $33.02 | $0.00 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · derivative · entry 30 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,399 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F21 · derivative.exercise_date: Currently exercisable. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 47,624 | $0.00 Strike: $33.02 | $0.00 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · derivative · entry 29 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,624 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F21 · derivative.exercise_date: Currently exercisable. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,410 | $0.00 Strike: $18.01 | $0.00 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · derivative · entry 28 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,410 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F21 · derivative.exercise_date: Currently exercisable. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,020 | $0.00 Strike: $33.02 | $0.00 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · derivative · entry 27 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,624 Underlying: Common Stock · 2,020 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F21 · derivative.exercise_date: Currently exercisable. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,475 | $0.00 Strike: $18.01 | $0.00 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · derivative · entry 26 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,410 Underlying: Common Stock · 2,475 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F21 · derivative.exercise_date: Currently exercisable. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 200 | $85.34 | $17,068.00 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · nonDerivative · entry 24 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,625 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F20 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.33 to $85.34 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,621 | $84.54 | $221,579.34 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · nonDerivative · entry 23 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,825 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F19 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $84.00 to $84.97 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 4,834 | $83.39 | $403,107.26 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · nonDerivative · entry 22 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,446 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F18 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $83.00 to $83.94 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,744 | $82.61 | $309,291.84 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · nonDerivative · entry 21 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,280 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F17 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $82.00 to $82.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 11,399 | $33.02 | $376,394.98 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · nonDerivative · entry 20 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,095 | $85.15 | $263,539.25 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · nonDerivative · entry 19 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,625 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F16 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.37 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 9,171 | $84.42 | $774,215.82 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · nonDerivative · entry 18 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,720 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F15 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $83.95 to $84.92 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 21,844 | $83.33 | $1,820,260.52 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · nonDerivative · entry 17 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,891 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F14 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $82.95 to $83.94 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 13,514 | $82.55 | $1,115,580.70 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · nonDerivative · entry 16 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,735 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F13 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $81.85 to $82.94 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 47,624 | $33.02 | $1,572,544.48 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · nonDerivative · entry 15 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,249 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 200 | $85.37 | $17,074.00 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · nonDerivative · entry 14 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,625 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F12 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.33 to $85.41 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,757 | $84.56 | $148,571.92 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · nonDerivative · entry 13 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,825 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F11 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $84.00 to $84.83 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,663 | $83.41 | $305,530.83 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · nonDerivative · entry 12 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,582 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F10 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $83.00 to $83.97 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,790 | $82.82 | $231,067.80 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · nonDerivative · entry 11 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,245 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F9 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $82.00 to $82.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 8,410 | $18.01 | $151,464.10 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · nonDerivative · entry 10 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 180 | $85.17 | $15,330.60 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · nonDerivative · entry 9 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,625 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F8 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.16 to $85.17 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 289 | $84.61 | $24,452.29 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · nonDerivative · entry 8 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,805 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $84.00 to $84.97 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 862 | $83.35 | $71,847.70 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · nonDerivative · entry 7 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,094 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $83.00 to $83.96 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 689 | $82.63 | $56,932.07 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · nonDerivative · entry 6 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,956 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $82.00 to $82.98 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,020 | $33.02 | $66,700.40 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · nonDerivative · entry 5 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 574 | $84.67 | $48,600.58 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · nonDerivative · entry 4 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,625 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $84.00 to $84.97 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 990 | $83.44 | $82,605.60 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · nonDerivative · entry 3 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,199 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $83.00 to $83.96 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 911 | $82.63 | $75,275.93 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · nonDerivative · entry 2 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,189 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $82.00 to $82.98 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,475 | $18.01 | $44,574.75 |
DisclosureSEC source: 0001578850-25-000007 · form4-11262025_051101.xml · nonDerivative · entry 1 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,101 | $0.00 Strike: $33.02 | $0.00 |
DisclosureSEC source: 0001578850-25-000006 · form4-11262025_051103.xml · derivative · entry 16 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,399 Underlying: Common Stock · 6,101 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F7 · derivative.exercise_date: Currently exercisable. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 21,206 | $0.00 Strike: $33.02 | $0.00 |
DisclosureSEC source: 0001578850-25-000006 · form4-11262025_051103.xml · derivative · entry 15 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,644 Underlying: Common Stock · 21,206 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F7 · derivative.exercise_date: Currently exercisable. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,715 | $0.00 Strike: $18.01 | $0.00 |
DisclosureSEC source: 0001578850-25-000006 · form4-11262025_051103.xml · derivative · entry 14 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,885 Underlying: Common Stock · 4,715 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F7 · derivative.exercise_date: Currently exercisable. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,650 | $0.00 Strike: $33.02 | $0.00 |
DisclosureSEC source: 0001578850-25-000006 · form4-11262025_051103.xml · derivative · entry 13 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,850 Underlying: Common Stock · 1,650 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F7 · derivative.exercise_date: Currently exercisable. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,900 | $0.00 Strike: $18.01 | $0.00 |
DisclosureSEC source: 0001578850-25-000006 · form4-11262025_051103.xml · derivative · entry 12 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,600 Underlying: Common Stock · 1,900 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F7 · derivative.exercise_date: Currently exercisable. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 6,101 | $80.17 | $489,117.17 |
DisclosureSEC source: 0001578850-25-000006 · form4-11262025_051103.xml · nonDerivative · entry 10 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,625 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $80.00 to $80.56 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 6,101 | $33.02 | $201,455.02 |
DisclosureSEC source: 0001578850-25-000006 · form4-11262025_051103.xml · nonDerivative · entry 9 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 21,206 | $80.19 | $1,700,509.14 |
DisclosureSEC source: 0001578850-25-000006 · form4-11262025_051103.xml · nonDerivative · entry 8 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,625 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $80.00 to $80.88 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 21,206 | $33.02 | $700,222.12 |
DisclosureSEC source: 0001578850-25-000006 · form4-11262025_051103.xml · nonDerivative · entry 7 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 4,715 | $80.15 | $377,907.25 |
DisclosureSEC source: 0001578850-25-000006 · form4-11262025_051103.xml · nonDerivative · entry 6 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,625 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $80.00 to $80.68 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.